
Opinion|Videos|October 28, 2024
Treatment Considerations for PSMA-Positive mCRPC Patients
Author(s)Neal Shore, MD, FACS
Key Takeaways
Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Annual ACS NCDB report details national trends in prostate cancer care
2
Treatment Selection in Advanced Prostate Cancer
3
Docetaxel plus tumor-targeting IL-12 yields promising activity in mCRPC
4
FDA provides guidance on development pathway for testosterone therapy for women
5


